Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

NCT02535299 on ClinicalTrials.gov · last registry update 2016-09-13

An unusually large phase 4: 200 participants, more than double the 75 typical for the stage. Its estimated completion date, December 2018, has passed with no update to the record. Primary outcome, as filed: physiological parameter:glycosylated hemoglobin A1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Third Military Medical University
Sponsor type: Other
Enrollment: 200
Started: 2016-06
Primary completion: 2018-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

physiological parameter:glycosylated hemoglobin A1c

Conditions studied

GLP-1；Metformin；Telomere-telomerase System；Par-4

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.